Skip to main content

Hemodynamic and antiischemic effects of intravenous elgodipine, a new dihydropyridine calcium channel blocker, in patients with chronic stable angina

Cardiovascular Drugs and Therapy volume 9, pages 595–600 (1995)Cite this article

Summary

Elgodipine is a new second-generation dihydropyridine calcium antagonist. Its hemodynamic and antiischemic properties were evaluated in a single-blind, placebocontrolled trial in 22 males with chronic stable angina. Coronary artery disease was angiographically confirmed. Measurements were performed with a Swan-Ganz thermodilution catheter during a 30-minute period of rest and before the end of a 4-minute bicycle exercise test at maximum individual workload, both with placebo (IV infusion of 5 ml saline over 30 minutes) and elgodipine (10 µg/kg/2 min bolus IV, then IV infusion of 1 µ/kg/min for 28 minutes. Elgodipine caused very similar hemodynamic changes at rest and during exercise. Its major hemodynamic modification was the marked decrease in systemic vascular resistance, which was accompanied by an increase in cardiac index and stroke volume. Mean arterial blood pressure was slightly reduced, whereas the opposite small increase in heart rate meant that the double product remained unchanged. Contrary to resting conditions, pulmonary capillary wedge pressure, pulmonary artery pressures, pulmonary vascular resistance, and mean right atrial pressure remained normal or increased to a lesser extent during exercise after elgodipine. After elgodipine ischemic ST depression during exercise was diminished, and 11 of 16 assessable patients remained free from angina pectoris. We conclude that elgodipine is an efficacious antianginal drug. Its major mechanism of action is lowering of systemic vascular resistance. Thus elgodipine improves systolic cardiac function in patients with chronic stable angina and may delay the onset of ischemic diastolic dysfunction during exercise, as indicated by a normal left ventricular end-diastolic pressure (LVEDP). The data also suggest an improvement in coronary blood flow during exercise.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Tejerina T, González P, López J, Tamargo J.4th International Symposium on Calcium Antagonists: Pharmacology and Clinical Research. Florence: Fondazione Giovanni Lorenzini, 1989:256.

    Google Scholar 

  2. Tejerina T, González P, Galiano A, Alguacil M, De Miguel B. Effects of elgodipine in vascular smooth muscle.Eur J Pharmacol 1990;183:552.

    Google Scholar 

  3. Román C, De Miguel B, Giráldez A, Galiano A. Study of agonism and antagonism of elgodipine on different types of receptors.Eur J Pharmacol 1990;183:2411–2412.

    Google Scholar 

  4. Sassen LMA, Soei LK, Koning MMG, Verdouw PD. The central and regional cardiovascular responses to intravenous and intracoronary administration of the phenyldihydropyridine elgodipine in anaesthetized pigs.Br J Pharmacol 1990;99:355–363.

    PubMed  Google Scholar 

  5. Van Woerkens LJ, Schotman SN, van der Giessen WJ, Verdouw PD. Cardiovascular effects of elgodipine in conscious pigs with a normal coronary circulation and in conscious pigs with a healed myocardial infarction.J Cardiovasc Pharmacol 1991;17:976–982.

    PubMed  Google Scholar 

  6. Suryapranata H, Maas A, MacLeod DC, de Feyter PJ, Verdouw PD, Serruys PW. Coronary vasodilatory action of elgodipine in coronary artery disease.Am J Cardiol 1992;69:1171–1177.

    PubMed  Google Scholar 

  7. Chaitman B. Exercise stress testing. In: Braunwald E, ed.Heart Disease: A Textbook of Cardiovascular Medicine, 4th ed. Philadelphia: W.B. Saunders, 1992:161–179.

    Google Scholar 

  8. Rousseau MF, Etienne J, Van Mechelen H, Veriter C, Pouleur H. Hemodynamic and cardiac effects of nicardipine in patients with coronary artery disease.J Cardiovasc Pharmacol 1984;6:833–839.

    PubMed  Google Scholar 

  9. Visser CA, Jaarsma W, Kan G, Koolen JJ, Lie KI. Immediate and long-term effects of nicardipine, at rest and during exercise, in patients with coronary artery disease.Br J Clin Pharmacol 1985;20:158S-162S.

    PubMed  Google Scholar 

  10. Vogt A, Kreuzer H. Hemodynamic effects of nisoldipine in chronic congestive heart failure.Drug Res 1983;33:877–879.

    Google Scholar 

  11. Silke B, Verma SP, Zezulka AV, et al. Haemodynamic and radionuclide effects of amlodipine in coronary artery disease.Br J Clin Pharmacol 1990;29:437–445.

    PubMed  Google Scholar 

  12. Roskamm H, Rentrop P, Petersen J. Die Ventrikelfunktion bei koronarer Herzerkrankung.Verh Dtsch Ges Kreislaufforschung 1976;42:50–62.

    Google Scholar 

  13. Lahiri A, Rodrigues EA, Carboni GP, Raftery EB. Effects of long-term treatment with calcium antagonists on left ventricular diastolic function in stable angina and heart failure.Circulation 1990;81(Suppl III):III130-III138.

    PubMed  Google Scholar 

  14. Serruys PW, Suryapranata H, Planellas J, et al. Effects of short-term intravenous administration of nisoldipine on left ventricular and coronary hemodynamics in patients with coronary artery disease.Am J Cardiol 1985;56:140–146.

    PubMed  Google Scholar 

  15. Tamargo J, López-Sendón J, Delpón E, González-Morales M, De Miguel E. Cardiovascular effects of the new dihydropyridine derivative elgodipine.Drug Res 1991;41(II):895–900.

    Google Scholar 

  16. Zacca NM, Verani MS, Chahine RA, Miller RR. Effect of nifedipine on exercise-induced left ventricular dysfunction and myocardial hypoperfusion in stable angina.Am J Cardiol 1982;50:689–695.

    PubMed  Google Scholar 

  17. Di Pasquale G, Lusa AM, Manini GL, Coluccini M, Bassein L, Pinelli G. Comparative efficacy of nicardipine, a new calcium antagonist, versus nifedipine in stable effort angina.Int J Cardiol 1984;6:673–684.

    PubMed  Google Scholar 

  18. Burger W, Herholz H, Burger K, Kober G. Antiischemic and hemodynamic effects of intravenous isradipine, a new calcium antagonist, in coronary heart disease: A comparative double-blind cross-over study with nifedipine.J Cardiovasc Pharmacol 1990;16:764–768.

    PubMed  Google Scholar 

  19. Detry J-MR, De Coster PM, Renkin J. Hemodynamic effects of felodipine at rest and during exercise in exertional angina pectoris.Am J Cardiol 1983;52:453–457.

    PubMed  Google Scholar 

  20. Engel HJ, Wolf R, Hundeshagen H, Lichtlen PR. Different effects of nitroglycerin and nifedipine on regional myocardial blood flow during pacing induced angina pectoris.Eur Heart J 1980;1(Suppl B):53–58.

    PubMed  Google Scholar 

  21. Wagniart P, Ferguson RJ, Chaitman BR, et al. Increased exercise tolerance and reduced electrocardiographic ischemia with diltiazem in patients with stable angina pectoris.Circulation 1982;66:23–28.

    PubMed  Google Scholar 

  22. Brodsky SJ, Cutler SS, Winer DA, McCabe CH, Ryan TJ, Klein MD. Treatment of stable angina of effort with verapamil: A double-blind, placebo-controlled randomized crossover study.Circulation 1982;66:569–574.

    PubMed  Google Scholar 

  23. Terrosu P, Ibba GV, Pes R, et al. Exercise cardiovascular responses to gallopamil in ischemic heart disease.Int J Cardiol 1991;33:75–82.

    PubMed  Google Scholar 

Download references

Author information

Affiliations

  1. Medizinsche Klinik II, Klinikum Lippe-Detmold, Akademisches Lehrkrankenhaus der Westfälischen Wilhelms-Universität Münster, Röntgenstr. 18, 32756, Detmold, Germany

    Andreas Kuhn, Jörg Carlsson, Sinisa Miketic & Ulrich Tebbe

Authors
  1. Andreas Kuhn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jörg Carlsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sinisa Miketic
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ulrich Tebbe
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kuhn, A., Carlsson, J., Miketic, S. et al. Hemodynamic and antiischemic effects of intravenous elgodipine, a new dihydropyridine calcium channel blocker, in patients with chronic stable angina. Cardiovasc Drug Ther 9, 595–600 (1995). https://doi.org/10.1007/BF00878092

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00878092

Key Words

  • elgodipine
  • calcium channel blocker
  • coronary artery disease
  • chronic stable angina
  • exercise
  • hemodynamics